scholarly journals Thymidine kinase in epithelial ovarian cancer: Relationship with the other pyrimidine pathway enzymes

2002 ◽  
Vol 99 (3) ◽  
pp. 328-335 ◽  
Author(s):  
Ritsuto Fujiwaki ◽  
Kohkichi Hata ◽  
Kentaro Nakayama ◽  
Masashi Moriyama ◽  
Osamu Iwanari ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Thymidine Kinase ◽  
The Other ◽  
Pyrimidine Pathway

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

1994 ◽  
Vol 12 (1) ◽  
pp. 60-63 ◽  
Author(s):  
P J Hoskins ◽  
K D Swenerton
Keyword(s):  
Ovarian Cancer ◽  
Confidence Interval ◽  
Epithelial Ovarian Cancer ◽  
Surface Area ◽  
Body Surface ◽  
Response Rate ◽  
The Other ◽  
Fixed Dose ◽  
Oral Etoposide ◽  
Platinum Resistant

PURPOSE To determine whether etoposide (VP16) is more effective when administered on a chronic schedule, women with clinically defined platinum-resistant epithelial ovarian cancer (EOC) were studied. PATIENTS AND METHODS Thirty-one eligible women were treated with oral VP16. The first seven received a dose that varied depending on their body-surface area, but this proved too toxic, and so a fixed dose of 100 mg orally per day for 14 days every 3 weeks was used for the other subjects. RESULTS The response rate was 26% (95% confidence interval [CI], 11% to 41%). The 28 women with cancer that had progressed while they were receiving a platinum analog had a response rate of 21% (95% CI, 6% to 36%). Response durations were short. CONCLUSION When administered on this chronic schedule, VP16 has activity against platinum-resistant EOC.

scholarly journals Uterine involvement in epithelial ovarian cancer and its risk factors

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Narges Zamani ◽  
Azam Sadat Mousavi ◽  
Setare Akhavan ◽  
Shahrzad Sheikhhasani ◽  
Somayeh Nikfar ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Uterine Cancer ◽  
Histological Type ◽  
The Other ◽  
Ca 125 ◽  
Study Patient ◽  
P Value ◽  
Ovary Tumor

Abstract Background Epithelial ovarian cancer (EOC) is an extremely aggressive and lethal carcinoma. Specific data that identify high-risk groups with uterine involvement are not available. Thus, this study aimed to evaluate a gross number of women with EOC to obtain the frequency of uterine involvement and its risk factors. Methods This retrospective observational study was conducted on 1900 histologically confirmed EOC women, diagnosed and treated in our tertiary hospital from March 2009 to September 2020. Data including their demographic, medical and pathological findings were collected. Results From 1900 histologically confirmed EOC women, 347 patients were eligible for participations. The mean age of study patients was 51.31 ± 11.37 years with the age range of 25 to 87 years. Uterine involvement was detected in 49.6% (173) of the patients either macroscopic (47.4%) or microscopic (52.6%) types. Uterine involvement was significantly associated with having AUB (P-value = 0.002), histological type of ovary tumor (P-value < 0.001), ovarian cancer stage (P-value < 0.001), and abnormal CA-125 concentration (P-value = 0.004). Compared to the other study patient, the patients with metastatic uterine involvement had significantly higher stage (p-value< 0.001), higher grade of ovary tumor (p-value = 0.008), serous histological type (p-value< 0.001), and a higher level of CA-125 concentration (p-value< 0.001). on the other hand, the patients with synchronous uterine cancer were significantly younger (p-value = 0.013), nulliparous (p-value< 0.001), suffered from AUB symptoms (p-value< 0.001) and had endometroid histological type (p-value = 0.010) of ovary cancer in comparison to other study patients. Conclusion Considering the high prevalence of uterine involvement in EOC patients, ultrasound evaluation and/or endometrium biopsy assessment should be done before planning any treatment.

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome

Die personalisierte Therapie beim Ovarialkarzinom

2018 ◽  
Vol 39 (03) ◽  
pp. 180-186
Author(s):  
Ann-K. Langner ◽  
Nina Pauly ◽  
Beyhan Ataseven ◽  
Andreas du Bois
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Personalisierte Medizin ◽  
Personalisierte Therapie

Die Behandlung des epithelialen Ovarial-, Tuben- und Peritonealkarzinoms (epithelial ovarian cancer; EOC) fußt auf 3 Säulen, die in unterschiedlichem Maße individualisierte bzw. personalisierte Medizin inkludieren:

BCL6 function and platin resistance in epithelial ovarian cancer

2018 ◽  
Author(s):  
M Eberhardt ◽  
N Häfner ◽  
D Kritsch ◽  
M Rengsberger ◽  
M Dürst ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document